References
- HHS: what is the U.S. opioid epidemic. Washington (DC): US Department of Health and Human Services; [cited 2019 Sep 4]; 2019. Available from: https://www.hhs.gov/opioids/about-the-epidemic/index.html
- HHS: secretary price announces HHS strategy for fighting opioid crisis. Washington (DC): US Department of Health and Human Services; [cited 2017 Apr 19]; 2017. Available from: https://www.hhs.gov/about/leadership/secretary/speeches/2017-speeches/secretary-price-announces-hhs-strategy-for-fighting-opioid-crisis/index.html
- SAMHSA: medication assisted treatment (MAT). Washington (DC): Substance Abuse and Mental Health Services Administration; [cited 2020 Jul 9]; 2020. Available from: https://www.samhsa.gov/medication-assisted-treatment
- SAMHSA: buprenorphine. Washington (DC). Substance Abuse and Mental Health Services Administration; [cited 2020 May 4]; 2020. Available from: https://www.samhsa.gov/medication-assisted-treatment/treatment/buprenorphine
- SAMHSA: statues, regulations, and guidelines. Washington (DC): Substance Abuse and Mental Health Services Administration; [cited 2020 Jul 22]; 2020. Available from: https://www.samhsa.gov/medication-assisted-treatment/statutes-regulations-guidelines
- American Society of Health-System Pharmacists: buprenorphine hydrochloride. Bethesda (MD). AHFS DI Essentials™; [cited 2020 Jul 24]; 2020. Available from: https://www.drugs.com/monograph/buprenorphine-buprenorphine-hydrochloride.html
- Lutfy K, Eitan S, Bryant CD, et al. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci. 2003;23(32):10331–10337.
- Mizoguchi H, Wu HE, Narita M, et al. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse. Neuroscience. 2002;115(3):715–721.
- AAPCC: National Poison Data System (NPDS). Arlington (VA). American Association of Poison Control Centers; 2017. Available from: https://aapcc.org/data-system
- Gummin DD, Mowry JB, Spyker DA, et al. 2018 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 36th annual report. Clin Toxicol. 2019;57(12):1220–1413.
- US Department of Justice, Drug Enforcement Administration. ARCOS retail drug summary reports. Springfield (MA). Drug Enforcement Administration. Available from: https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary
- SAMHSA: trends in the use of methadone, buprenorphine, and extended release naltrexone at substance abuse treatment facilities: 2003–2015 (update). Washington (DC). Substance Abuse and Mental Health Services Administration; [cited 2017 Aug 22]; 2017. Available from: https://www.samhsa.gov/data/sites/default/files/report_3192/ShortReport-3192.html
- Roberts AW, Saloner B, Dusetzina SB. Buprenorphine use and spending for opioid use disorder treatment: trends from 2003 to 2015. Psychiatr Serv. 2018;69(7):832–835.
- Lavonas EJ, Severtson SG, Martinez V, et al. Abuse and diversion of buprenorphine sublingual tablets and film. J Subst Abuse Treat. 2014;47(1):27–34.
- Lofwall MR, Havens JR. Inability to access buprenorphine treatment as a risk factor for using diverted buprenorphine. Drug Alcohol Depend. 2012;126(3):379–383.
- Strang J, Knight A, Baillie S, et al. Norbuprenorphine and respiratory depression: exploratory analyses with new lyophilized buprenorphine and sublingual buprenorphine. Int J Clin Pharmacol Ther. 2018;56(2):81–85.
- Huang P, Kehner GB, Cowan A, et al. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther. 2001;297(2):688–695.
- Yassen A, Kan J, Olofsen E, et al. Pharmacokinetic–pharmacodynamic modeling of the respiratory depressant effect of norbuprenorphine in rats. J Pharmacol Exp Ther. 2007;321(2):598–607.
- Alhaddad H, Cisternino S, Declèves X. Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood–brain barrier in mice. Crit Care Med. 2012;40(12):3215–3223.
- Reynaud M, Tracqui A, Petit G, et al. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am J Psychiatry. 1998;155(3):448–449.
- Tracqui A, Kintz P, Ludes B. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol. 1998;22(6):430–434.
- Gaulier JM, Marquet P, Lacassie E, et al. Fatal intoxication following self administration of a massive dose of buprenorphine. J Forensic Sci. 2000;45(1):226–228.
- MEDSAFE. Drug metabolism—the importance of cytochrome P450 3A4. New Zealand Medicines and Medical Devices Safety Authority; [cited 2014 Mar 6]; 2014. Available from: https://www.medsafe.govt.nz/profs/puarticles/march2014drugmetabolismcytochromep4503a4.htm
- Fox LM, Hoffman RS, Vlahov D, et al. Risk factors for severe respiratory depression from prescription opioid overdose. Addiction. 2018;113(1):59–66.
- Hedegaard H, Miniño AM, Warner M. Drug overdose deaths in the United States, 1999–2018. NCHS data brief no. 356. Hyattsville (MD): US Department of Health and Human Services, CDC, National Center for Health Statistics; 2020.